April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
January 2017 in “The American Pharmacists Association eBooks” January 2017 in “The American Pharmacists Association eBooks” December 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” A new combination of tadalafil and finasteride improves drug performance and stability.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
March 2005 in “Current Prostate Reports”
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
32 citations
,
June 2012 in “PLoS ONE” Blocking IL-8 can reduce skin rashes from cancer treatment.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
January 2015 in “Faculty of 1000 Research Ltd” BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
Finasteride treatment increased blood volume and reduced vessel leakiness in beagle prostates.
7 citations
,
September 1997 in “PubMed” April 2017 in “The Journal of urology/The journal of urology” SHH protein helps nerve regeneration in hypertensive rats.
46 citations
,
July 2010 in “Advances in Therapy” SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.
16 citations
,
November 2018 in “The journal of pain/Journal of pain” 14,15-EET may help reduce poststroke pain by affecting certain brain proteins.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
September 2004 in “Inpharma Weekly”
40 citations
,
April 1999 in “Drugs” Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
1 citations
,
December 2023 in “Curēus” Tadalafil is effective for treating urinary symptoms in men with BPH.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
6 citations
,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
3 citations
,
April 2016 in “Research and reports in urology” The new saw palmetto extract effectively inhibits an enzyme linked to prostate enlargement and may be as good as standard treatments.
June 2018 in “The Journal of Sexual Medicine” Finasteride helps female-pattern hair loss.
1 citations
,
July 2022 in “Frontiers in Pharmacology” Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.